MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

216.03 +14.07 (+6.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,374,526
Open 202.52
Bid (Size) 214.00 (300)
Ask (Size) 217.00 (500)
Prev. Close 201.96
Today's Range 202.53 - 218.06
52wk Range 121.05 - 218.06
Shares Outstanding 146,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Biogen (BIIB) Stock Is Up Today
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued to cheer a string of growth sign... 
Via StockStory
Topics Artificial Intelligence Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
+21.5%
+21.5%
1 Month
+10.2%
+10.2%
3 Month
+15.2%
+15.2%
6 Month
+22.2%
+22.2%
1 Year
+72.0%
+72.0%

More News

Read More
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
Via StockStory
Topics Artificial Intelligence
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Via Investor Brand Network
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire
News headline image
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
From Biogen Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
From Pomerantz LLP
Via GlobeNewswire
News headline image
3 Overrated Stocks Walking a Fine Line
Via StockStory
News headline image
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
Via StockStory
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
From Pomerantz LLP
Via GlobeNewswire
News headline image
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. ↗
Via The Motley Fool
News headline image
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
From Biogen Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
From Pomerantz LLP
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 05/18 - 05/22 ↗
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish ↗
Via MarketBeat
News headline image
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push ↗
Via MarketBeat
Stay informed with the top movers within the S&P500 index on Thursday. ↗
Via Chartmill
News headline image
Best Healthcare Stocks to Buy in 2026 ↗
Via The Motley Fool

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 216.03
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 06/26/26 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 31.71B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 32B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story